Current Edition


Bristol Myers CEO Caforio takes pay cut as ‘human capital’ metric drags down bonus

Bristol Myers Squibb is hoping new launches will offset a wave of forthcoming patent losses for some of its biggest-selling drugs. But in the meantime, …

Continue Reading →
ASH 2021

ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T meds

Kymriah’s shocking failure in earlier lymphoma treatment has raised doubts about the Novartis drug’s potency in light of impressive victories from rival CAR-Ts by Gilead …

Continue Reading →